Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Working Capital Changes: 2020-2025

Historic Other Working Capital Changes for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $2.4 million.

  • Apellis Pharmaceuticals' Other Working Capital Changes rose 147.84% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 121.00%. This contributed to the annual value of -$20.4 million for FY2024, which is 43.37% down from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Other Working Capital Changes stood at $2.4 million, which was up 129.98% from -$8.0 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Other Working Capital Changes peaked at $47.6 million during Q4 2021, and registered a low of -$44.5 million during Q2 2022.
  • In the last 3 years, Apellis Pharmaceuticals' Other Working Capital Changes had a median value of -$5.0 million in 2024 and averaged -$2.0 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Other Working Capital Changes slumped by 2,792.68% in 2022, and later soared by 642.30% in 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Other Working Capital Changes (Quarterly) stood at $47.6 million in 2021, then crashed by 73.70% to $12.5 million in 2022, then tumbled by 275.10% to -$21.9 million in 2023, then soared by 75.38% to -$5.4 million in 2024, then surged by 147.84% to $2.4 million in 2025.
  • Its Other Working Capital Changes was $2.4 million in Q3 2025, compared to -$8.0 million in Q2 2025 and $18.7 million in Q1 2025.